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1 Introduction 
There has been a rapid growth in the availability of novel psychoactive substances (NPS), labelled ‘legal 
highs’, ‘designer drugs’, ‘synthetic drugs’, ‘bath salts’, and ‘research chemicals’ over the last number of 
years (Simonato et al., 2013; ACMD, 2011; Zawilska & Andrzejczak, 2015). NPS have been described by 
the Advisory Council on the Misuse of Drugs (ACMD) as, ‘psychoactive drugs which are not prohibited by 
the United Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs Act 1971, and which 
people in the UK are seeking for intoxicant use’ (ACMD, 2011). These substances have been persistently 
considered as legal alternatives to other illicit drugs of abuse (Deluca et al., 2012) although several of 
these products are packaged with warnings stating “not for human consumption”. 1.1  Ireland and NPS 
Research to date on NPS use in Ireland are limited to a small number of qualitative studies (McElrath & 
O’Neill, 2011; McElrath & Van Hout, 2011; Ryall & Butler, 2011; Smyth et al., 2015; Van Hout & Brennan, 
2011a,b,c; 2012; Van Hout & Bingham, 2012; Van Hout & Hearne, 2015a), reviews (Connolly, 2014; 
Dowling et al., 2013; Kavanagh & Power, 2014; Kelleher et al., 2011; Van Hout, 2013) and government 
reports (Department of Community, Rural & Gaeltacht Affairs, 2009; Department of health, 2013a,b). 
Research on NPS in the Republic of Ireland to date has focused on the pre and post legislative detection 
of NPS and in particular the popular synthetic cathinone “mephedrone” (Van Hout & Hearne, 2015a). BZP 
i.e. 1-benzylpiperazine was the first NPS in Ireland to be controlled via a Statutory Instrument (S.I. No. 
122/2009) in 2009. BZP had already been banned in New Zealand in 2008, the same year it surfaced in 
Ireland as a replacement for MDMA at that time (Kavanagh & Power, 2014). In April 2010, the UK banned 
mephedrone and cathinone derivatives, and in line with the Misuse of Drugs Act (1971) indicated criminal 
penalizations for possession and supply of those substances. One month after this ban, the Republic of 
Ireland went on to ban mephedrone and related cathinones (McElrath & Van Hout, 2011). 2 Current Irish Drug Policy 
Drug Policy has been defined as “a system of laws, regulatory measures, courses of action and funding 
priorities concerning (illicit) psychoactive drugs and promulgated by a governmental entity or its repre-
sentatives” (Kilpatrick, 2000). The Irish Presidency Steering Group on Drug Issues which was set up in 
early 2012 (Department of Health, 2013b; Pike, 2013) under the leadership of The Drug Policy Unit (De-
partment of Health (DOH)) includes a small number of officials from the DOH, Department of Foreign 
Affairs & Trade, and the Department of Justice & Equality. This steering group is derived from the Inter-
national Drug Issues Group (IDIG) which brings together Irish drug policy responses on the international 
stage each yearly quarter (Pike, 2013). 
Ireland’s developments in illicit drug policy have followed a remarkable course, with comparisons and 
differences to that experienced in other European countries (EMCDDA, 2013). In September 2009 a new 
‘National drugs strategy (interim) 2009–2016’ was launched, which reiterated previous approaches im-
plemented in 1996 and 2001 such as the collaboration of representatives from statutory, voluntary and 
community sectors (Ministerial Task Force on Measures to Reduce the Demand for Drugs, 1996; Quigley, 
2010; EMCDDA, 2013) and an increase in public involvement in drug policy developments (Pike, 2008). 
The pillar model that previously provided structure (Drug Misuse Research Division, 2001; Pike, 2008) 
covering the areas of: supply reduction; prevention; combined treatment and rehabilitation; research and 
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information; and co-ordination, was also retained in the new strategy. Public consultation meetings high-
lighting concern for illicit and NPS drugs were held throughout the development phase of the new drug 
strategy, and the collaboration between community, statutory and voluntary sectors was again support-
ed in the document (EMCDDA, 2013). 
The new Drugs Strategy called for the Department of Health (DOH) to review prevailing laws and to se-
cure loopholes that facilitated the legal sales of NPS (Department of Community, Rural and Gaeltacht 
Affairs, 2009). Consequently, several drug-related policy and legislative changes were introduced from 
2009 onwards in order to address the issue of NPS (EMCDDA, 2013). 2.1  Drug Law, NPS and Ireland  
The National Drugs Strategy (NDS) (interim) 2009–2016 specifies the working framework for drugs policy 
of illicit drugs in Ireland (Department of Community, Rural and Gaeltacht Affairs, 2009). The Strategy has 
a general strategic objective ‘To continue to tackle the harm caused to individuals and society by the mis-
use of drugs through a concerted focus on the five pillars of supply reduction, prevention, treatment, re-
habilitation and research’ (Health Research Board, Irish Focal Point, 2013). The National Advisory Com-
mission on Drugs (NACD)’s sub-group the “Early Warning System” informs the EMCDDA and Europol 
when new substances or cases of interest are discovered in Ireland (Department of Health, 2013a). 
In the Republic of Ireland, the primary legislation controlling drugs are the Misuse of Drugs Act 1977 and 
the Misuse of Drugs Act, 1984. These are further amended by the Criminal Justice Act 1999, the Criminal 
Justice Act 2006 and the Criminal Justice Act 2007. The Misuse of Drugs Regulations 1988 (SI 328 of 1988) 
(as amended) registers the different substances to which legislation affects and has two main purposes 
which establish a control system over specific substances so as to protect the public from dangerous or 
possibly dangerous or harmful substances. It also enables safe use of specific controlled substances 
which, even though it can be harmful if misused, has therapeutic and medical significance. As per this 
legislation, unless specifically authorised to do so, it is illegal to possess, supply, manufacture, import or 
export a controlled substance (for example stimulants, cannabinoids, or hallucinogens). 
Controlling of substances under the Misuse of Drugs Act, works in collaboration, engagement, and com-
pliance with international structures such as the United Nations conventions, which provides an interna-
tional legal framework that addresses the phenomenon of illicit drugs. These frameworks are aimed at 
protecting the health of individuals from improper use of controlled substances, and also to ensure use of 
controlled substances is limited to scientific and medical purposes. 
The classification of drugs and precursors in Ireland reflects the three United Nations conventions of 
1961, 1971 and 1988. Criminal offences in Ireland are defined as the importing, manufacturing, posses-
sion and trade in, other than by prescription, of most psychoactive substances. The primary criminal legis-
lative framework is defined in the Misuse of Drugs Acts (MDA) 1977 and 1984, and the Misuse of Drugs 
Regulations 1988. The offences of drug possession (s.3 MDA) and possession for the purpose of supply 
(s.15 MDA) are the primary forms of criminal charge used in the prosecution of drug offences in Ireland. 
The Misuse of Drugs Regulations 1988 list under five schedules the various substances to which the law 
applies (Health Research Board, Irish Focal Point, 2013). 
NPS are regulated both by individual listing and a generic system. The legal foundation forming these 
systems is: s.2(2) of the Misuse of Drugs Act 1977; and Governmental Declaration Orders. A memoran-
dum is normally drafted and then submitted to the appropriate Governmental Departments for com-
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ments. After inclusion of these commentaries, along with the issue of a Declaration Order, the Minister 
for Health and Children then forwards the draft to the Government Cabinet of Ministers. Once this Decla-
ration Order has been approved, the Prime Minister will sign it. Then along with any associated regula-
tions or exemption orders, the Declaration Order is put forward to the Houses of the Oireachtas (Lower 
And Upper Houses) within 21 sitting days (the statutory time frame relative to the Misuse of Drugs Act); 
subsequently, they are then published in the Irish State Gazette. This process can take up to 6 weeks, 
though it sometimes can be longer if delays transpire. The process is the same irrespective of the guide-
lines for placement of new substances under control (EMCDDA, 2009). 2.2  NPS, Public Pressure and Changes to the Law in Ireland 
Street based headshops were blamed for the apparent extent of NPS use, mostly amongst youths, in the 
Republic of Ireland. In 2009-2010, resistance within communities, towards these headshops and the pro-
prietors, involved social media petitions such as on Facebook, protests at shop-fronts, arson attacks, 
shootings, bomb threats, and plans to completely ban headshops (Van Hout & Brennan, 2011a; Van Hout, 
2013). Much media attention and accounts of youths experiencing complications with NPS fuelled this 
public reaction and were the key factors that contributed to legislative controls over cathinones and a 
multitude of other NPS in the Republic of Ireland in May 2010 (Coomber et al., 2013). This spurred the 
government into a rapid and radical response (Ryall & Butler, 2011). 
The headshop controversy in Ireland and the resulting legislation is set in the framework of the concept 
of “moral panic” (Connolly, 2012). It has been described as “the negative societal consequences of psy-
choactive drug use tend to be exaggerated – by the media and a range of other “moral entrepreneurs” – 
thereby serving to legitimate extreme policy responses which, paradoxically, may amplify the very devi-
ance they were intended to curtail” (Ryall & Butler, 2011, pp. 304). 
Over 200 substances were controlled under the Misuse of Drugs Act 1977 (Controlled Drugs) (Declara-
tion) Order 2010. Consequently, the Criminal Justice (Psychoactive Substances) Act was implemented. 
This was an innovative “catch-all” law that would render the sale of any psychoactive substance illegal 
(Criminal Justice (Psychoactive Substances) Act 2010). In November 2011, the Misuse of Drugs (Con-
trolled Drugs) Declaration Order controlled 60 other substances including synthetic cannabinoids and 
cathinones (Reitox National Focal Point, 2011). Ireland’s legislation in 2010 and 2011 has been successful 
in limiting the sale of NPS. This was accomplished through a combination of endeavours of numerous 
statutory agencies and governmental departments (Health Research Board, 2012). 
Ireland broadened the capacity to control substances, and included a wider range of substances in the 
Criminal Justice (Psychoactive Substances) Act 2010. Several headshop products in Ireland were made 
illegal on 23 August 2010 when the new Criminal Justice (Psychoactive Substances) Act 2010 was passed 
(Van Hout & Hearne, 2015a). This act is applicable to substances that are not explicitly prohibited under 
the Misuse of Drugs Acts, although their effects are psychoactive, by making it illegal to sell, import, ex-
port or advertise such psychoactive substances. Legislation controlling 200 psychoactive substances was 
also passed in Ireland in May 2011 under the Misuse of Drugs Act 1977 and 1984. These substances in-
cluded: benzylpiperazine derivatives, mephedrone, synthetic cannabinoids, methylone and related cathi-
nones, GBL and 1, 4 BD, ketamine, and Tapentadol. Prior to this ban it was reported that legal headshops 
in Ireland were opening in January 2010 at approximately one per week (Van Hout, 2013). 
The objectives of the Criminal Justice (Psychoactive Substances) Act 2010 are to prevent the misuse of 
harmful substances (Van Hout & Hearne, 2015a). This gave the Irish police – An Garda Síochána, and the 
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Irish courts the power to prohibit sales of psychoactive substances in the case that such substances were 
not listed on under the Misuse of Drugs Act, or if they were represented on their packaging as ‘not for 
human consumption’, which is often the case (Van Hout, 2013). The Act took a new, non-traditional slant 
towards drug misuse and supply. It was explicitly aimed at vendors/suppliers and it was an endeavour 
that forced the closure of Irish headshops. The Act states that ‘a person who sells a psychoactive sub-
stance knowing or being reckless as to whether that substance is being acquired or supplied for human 
consumption shall be guilty of an offence’. However there are exceptions for sales of alcohol and tobac-
co, and medicines, which are governed under different legislation (Kavanagh & Power, 2014). 
An emergency piece of legislation, the Misuse of Drugs (Amendment) Act 2015, was ratified as a result of 
a Court of Criminal Appeal ruling banning possession of over 100 drugs, which included some psychoac-
tive substances, was unconstitutional This Act stipulates that each statutory instrument intended in 
Schedule 2 of the Act will hold statutory effects just as though it were an Act of the Oireachtas. This legis-
lative revision stipulates that substances that have been controlled before the court judgment by means 
of Government order, be appended to the Schedule of the 1977 Act (Van Hout & Hearne, 2015a). 
The apparent success in Ireland of legislative changes governing NPS may be judged by Smyth et al. 
(2015) who reported considerable reductions in NPS use amongst adolescents who were entering treat-
ment 6-12 months post legislation also. The report took a broad look at NPS use so as not to conceal use 
of other emerging substances i.e. not yet controlled NPS, while reducing use of just one single substance 
(Dargan et al., 2011). Additional new substances did surface on the drugs marketplace in the Republic of 
Ireland post legislation (O’Byrne et al., 2013; Kavanagh & Power, 2014). Nonetheless, the report showed 
a decrease in the whole group of NPS use (Smyth et al., 2015) 
Irish legislation blanket bans all psychoactive substances. Under this legislation, psychoactive substances 
are defined substances that stimulate or depress the central nervous system and are associated with 
dependency, hallucinations or disturbances in motor function and/or behaviour. Exemptions are imple-
mented for substances such as alcohol, caffeine and tobacco as per the Criminal Justice (Psychoactive 
Substances) Act 2010. Information on “gray areas” in Irish drug law is limited. However, recently Ireland’s 
Minister for Drugs, Aodhdan O Riordain, commented on the issues with NPS and how re-packaging makes 
it difficult for authorities to control, resulting in legal “grey areas”. His comments were stated after the 
death of a young man in Cork who ingested the substance “25i-nbome” (O’Regan, 2016). 
Research on novel psychoactive substances in Ireland to date have essentially focused on the pre and 
post legislative exposure of psychoactive substances, and the consumption of the synthetic cathinone 
mephedrone (Van Hout & Brennan, 2012; Van Hout & Bingham, 2012). Research by Kavanagh & Power 
(2014) scrutinizes the impact law enforcement and legislation has on the emergence of NPS and com-
monly named ‘headshops’ in Ireland in recent years. The research particularly considers the adverse im-
pact legislative controls of NPS have had on academic research in this area (Connolly, 2014). The authors 
suggest reviewing current legislation to allow for academic input that is more targeted towards NPS, alt-
hough they recognize that affiliations between forensic science and academia can be challenging due to 
some of the work of the forensic scientists may include substances that may be sub judice. Nonetheless, 
they contend that Irish legislation should ‘provide better mechanism for academia and forensic service 
providers to work together and share data so that more informed policy decisions can be made’ (Ka-
vanagh & Power, 2014, pp. 6). 
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2.3  Public Health Education and NPS in Ireland 
Ireland’s National Drugs Strategy provides education programmes in school settings and education pro-
grammes in non-school settings, including diversionary programmes primarily developed in Local Drugs 
Task Force (LDTF) areas. Ireland’s Department of Education and Science has numerous substance use 
education programmes in place that are intended to recognise and provide supports to children/youths 
at risk of substance use/misuse. These programmes include Youth Encounter Project Schools and the 
National Educational Psychological Service (NEPS) in school settings (Department of Community, Rural & 
Gaeltacht Affairs, 2009). The Department offers assistance to schools in fostering substance misuse poli-
cies; however the key responsibility in the development and implementation of these policies is with the 
schools themselves 
For those developing and providing education programmes, the greatest challenge when addressing NPS 
is dealing with users (or prospective users) naivety around their use such as route of administration ROA, 
dosing, and psychoactive effects, and probably the most worrying – the flawed assumption that the ex-
pression “legal high” somehow renders these substances as regulated and/or tested, and therefore safe 
(Mentor ADEPSIS, 2014). 
The Social Personal Health Education (SPHE) Programme is considered the basis for the development of 
drug and alcohol awareness in schools. This programme is mandatory in second level education in Ire-
land. The SPHE programme is intended to develop confidence and esteem within young people/school-
goers through the development of life skills, with substance misuse a fundamental part of the school 
curriculum While most education guidance and policy in Ireland is centred on all areas of substance mis-
use, Van Hout & Hearne’s (2015b) report on synthetic cannabinoid use recommends consultation with 
Primary and Secondary schools so as to what supports need to be in place for those delivering SPHE 
modules so they can include NPS, synthetic cannabinoids and/or emerging trends in NPS use (Depart-
ment of Community, Rural & Gaeltacht Affairs, 2009). 3 NPS Drug Market in Ireland 
Throughout 2009 and 2010, mephedrone was located in drug scenes within Britain (Carhart-Harris, King, 
& Nutt, 2011; Measham et al., 2010; Winstock et al., 2011) in Northern Ireland (greater Belfast area) 
(McElrath & O’Neill, 2011) and in Southern Ireland (Waterford, Wexford, Kilkenny & Carlow) (Van Hout & 
Brennan, 2011a), and was obtainable for sale/purchase through numerous sources such as dealers 
(McElrath & O’Neill, 2011), street-based headshops (Van Hout & Brennan, 2011a), and online vendors 
(European Monitoring Centre for Drugs and Drug Addiction, 2010; McElrath & Van Hout, 2011). Although 
there has been closure of all headshops in Ireland, and products are not openly for sale, it is common 
knowledge that these are still available and accessible on both the black market or on the internet (Kelle-
her et al., 2011). A study by (Van Hout & Hearne, 2015a) although limited to small communities in North 
Eastern Ireland (Monaghan), emphasizes the rising concerns around synthetic drug market dynamics in 
Ireland. 
The most recent 2010/11 general population survey in Ireland reported 3.5% of adults and 6.7% of young 
adults (15-34) used NPS such as party pills or herbal highs, herbal smoking mixtures, or powders such as 
cathinones during the 12 months prior to the survey. NPS use has seemed to be decreasing since the 
introduction of legislation in 2010 and 2011, demonstrated by a reduction in the number of unfavourable 
incidents reported. A reduction in the detection of cathinone derivatives was also noted via screening of 
  
9 
 
methadone program clients between 2010 and 2012 (Health Research Board, 2015a). The National Stu-
dent Drug Survey of Ireland reported a significant decline in the use of synthetic substances (Bingham, 
O’Driscoll & De Barra, 2015). 3.1  False labelling 
Kelleher et al. reported (2011) that of all types of NPS powdered substances in Ireland packaging listed 
the least amount of information on product contents, 79% of these products did not list any ingredients. 
The packaging seldom suggests the presence of psychoactive substances in the ingredient listings (where 
a list exists), however there often is none (See Fig. 1&2) (Psychonaut WebMapping Research Group, 
2009; Kavanagh et al., 2010; Europol-EMCDDA, 2010; Gibbons & Zloh, 2010). In comparison, 75% of the 
tablet form NPS and 67% of the capsule type products in Irish head shops had a list of ingredients. Herbal 
mixtures did not list ingredients (Kelleher et al., 2011). 
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Figure 1. Pre-Legislation Labelling 
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Figure 2. Active Constituents Identification Chart (June /July 2010) 
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4 NPS Prevalence and Use 
Interest in the use of mephedrone in Ireland, prior to legislative controls, was associated with safety (as 
perceived by users) perceived low potential for harm; competitive prices; and widespread availability 
online (Van Hout & Brennan, 2011a; Van Hout & Bingham, 2012). Ireland has one of the most compre-
hensive datasets on mephedrone detected in biologic al samples (human hair, tissues, urine, and blood) 
(others are in the United Kingdom and Sweden). In Ireland, mephedrone products were reportedly used 
combined with, or as a substitute for heroin (Europol-EMCDDA, 2010). 
A Northern Ireland qualitative study carried out ten weeks post UK legislation investigated sources of 
mephedrone supply (McElrath & O’Neill, 2011). The study illustrated a developing market for illicit supply 
of mephedrone, with users stating an increase in reliance of dealers, increased prices, and label-
ling/packaging differences (McElrath & Van Hout, 2011). The participants in this study reported positive 
mephedrone experiences, nonetheless they revealed awareness that the legality of the substance did not 
suggest total safety when used (McElrath & O’Neill, 2011; Kelly et al., 2013). 
Van Hout & Brennan (2011a) illustrated how participants had previous experiences with illicit street drugs 
and had used these as well as NPS products regularly, over the previous 6 month period. At the time of 
the study, along with cannabis, alcohol, cocaine, ecstasy and other NPS products, Mephedrone was most 
commonly procured from other users. Participants of the study explained their reasons for use of 
mephedrone as initially being based on numerous consumptive decision-making features including, curi-
osity, widespread availability, exposure, use among peers, and competitive cost. Furthermore, the partic-
ipants noted that in comparison to illicit street drugs such as cocaine or ecstasy, mephedrone strength, 
purity and effect was positive; they also reported an absence of negative comedown symptomatologies, 
which further supported their decisions around mephedrone initiation. 
It is often a challenge to estimate the prevalence of NPS use, particularly through surveys of the general 
population. The 2014 Flash Eurobarometer offers insight into this area, via a survey of some 13,000 
young adults in the EU member states and aged 15-24, asking about their NPS use. The survey found that 
8% of respondents had used an NPS at least once, and 3% of those were in the previous year. The highest 
rates of NPS use were found to be Ireland (9%), France, Spain (both 8%), and Slovenia (7%). The lowest 
rates of use were reported by Cyprus and Malta (0%). The majority of respondents who had used an NPS 
substance in the previous year had either been given them or purchased them from a friend (68%). 
Around 27% of them had purchased from a drug dealer; 10% from a “specialised” shop (headshop); and 
3% purchased on the internet (EMCDDA, 2015a). An EU survey carried out in June 2011, reported that of 
the 27 EU countries, Ireland was ranked first for the use of NPS, with the UK following closely at fourth 
(Newcombe, 2013). The European Commission reported (2011) that the lifetime prevalence of NPS use 
amongst youths was 5% throughout Europe, and at its highest in Ireland (16%). In May 2010 the amount 
of headshops in Ireland had risen to 102 – which equates to one headshop per 45,000 people (Kelleher et 
al., 2011) However, following the changes to the law, these headshops have closed so that trading is now 
‘underground’. Research has indicated a significant use and continuing easy access to NPS, regardless of 
legislation/bans (McElrath & O’Neill, 2011; Smyth et al., 2015) however the 2015 National Student Drug 
Survey of Ireland reported a noteworthy decrease in the use of synthetic substances (Bingham, O’Driscoll 
& De Barra, 2015). 
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4.1  Routes of Administration 
Although NPS can be considered heterogeneous, they can however, be mostly grouped by their route of 
administration: 1) stimulant NPS, powdered substances (mostly cathinones), are generally administered 
via insufflation (snorting) (Winstock, Mitcheson & Marsden, 2010); 2) amphetamine type stimulants in 
tablet form (often Piperazines) are taken orally (Kavanagh & Power, 2014; Smyth et al., 2015). 3) synthet-
ic cannabinoids are administered via inhalation (smoking) (Dargan et al., 2011); 4) a recent trend of NPS 
use is within the dissociative family, where these powdered substances are administrated by either insuf-
flation, oral or injection (Craig & Loeffler 2014; WHO, 2014; Van Hout & Hearne, 2015b). 
Van Hout and Brennan’s (2011a) Irish study reported that preferred route of administration for 
mephedrone appeared to be insufflation, from a coin dipped in the mephedrone (bumping) or in lines; 
and ranges from 0.5 to 2g, frequently administered over the course of a mephedrone episode – generally 
6 to 12 hours in length. The majority of participants professed “to trust their own judgement” based on 
past experiences of mephedrone use, in relation to the frequency of administration and reaching the 
desired mephedrone rush/high. The remaining participants considered novice users, took advice on ad-
ministering the substance from headshop staff and their peers. 4.2  Demand Recent Trends 
The use of headshop products prior to legislation in north and southern Ireland was common amongst a 
variety of drug using cohorts, in all classes, and included recreational drug using adolescents, PWID, and 
psychonauts (McElrath & Van Hout, 2011; Ryall & Butler, 2011; Van Hout & Brennan, 2011a; Van Hout & 
Bingham, 2012; Van Hout, 2013).Many Irish and Northern Irish studies reported on the cross border use 
of headshop products emphasising the effect of large scale drug market influences on consumer choices 
to purchase headshop substances, at a time when street drugs such as amphetamine, MDMA, and co-
caine were poor quality (McElrath & O Neill, 2011; Van Hout & Brennan, 2011a; b; McElrath & Van Hout, 
2011; Kelleher et al., 2011; Van Hout & Bingham, 2012; Van Hout, 2013). 
While Irish NPS users stated their intentions to maintain use of headshop products, follow-up studies 
reported users ceasing NPS use and reverting back to illicit street drug sourcing/use (Van Hout & Bren-
nan, 2012; Van Hout & Bingham, 2012). This was seemingly due to users negative “come up” and “come-
down” experiences such as psychosis with continued use of NPS over time; increase in price; concerns 
around contamination; and a rise in the development of improved quality illicit street drugs such as am-
phetamine, MDMA and cocaine post legislation (Van Hout & Brennan, 2012; Van Hout, 2013). 
A report by Irish Focal Point (2014) reported that with regard to NPS use amongst Irish people, 53% felt 
that a ban should only be put in place if the substance posed risks to health, 29% felt that regardless of 
the circumstance they should be banned, and 17% felt that regulation would be best. Ireland’s 2010 
blanket ban led to the closure of all headshops nationwide. Reports have shown that this considerably 
reduced NPS use amongst youths in Ireland (Smyth et al., 2015). Nonetheless, NPS use has not been 
completely eliminated, with reports of morbidity and mortality related to ongoing NPS use. This law is 
challenging to enforce, as it is determined by scientists who endeavour to prove the psychoactive effects 
of the substances, which is complex (Easton, 2015). Even though stricter legislation may reduce the use of 
NPS, complete elimination is unlikely (Gilani, 2015). 
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4.3  Socially Marginalised Users 
Data on NPS use among socially marginalised individuals in Ireland is limited. Of interest and in contrast 
to previous literature on mephedrone as a party and internet drug, a study by Van Hout and Bingham 
(2012) noted that 7 participants of the study were homeless. It was reported that these individual’s prac-
ticed groin and street injecting frequently. Mephedrone based products at that time were said to be the 
ideal ‘homeless persons’ drug’. Prior to the study, some charities based in Dublin had shown concerns 
relating to the injecting of these NPS products among the homeless population in late 2009 (see 
www.dublinpeople.com). Another Irish study reported pockets or clustering of synthetic cannabinoid use 
in a small community related to: accessibility; users living in deprived or marginalised areas; social net-
works of users; and penetrating into more mainstream communities (Van Hout & Hearne, 2015a). 4.4  Night Life Users 
Data on night life users of NPS in Ireland is also limited. Past research, while exploratory and regional by 
context, reported that mephedrone use was popular in Ireland within polydrug user groups, with user 
practices of consuming mephedrone supported by prior drug taking experiences and involvement in the 
dance music scene (Van Hout & Brennan, 2011a). Irish research described how mephedrone users dis-
cussed powerful individualistic experiences within a variety of socially suitable group contexts e.g. night-
clubs, dance music festivals, at parties, and in houses (Van Hout & Brennan, 2011b). 
Research carried out with a small group of nightclub users in Ireland post legislation, indicated a reduc-
tion in the use of mephedrone, with less than half of the participants reporting continued use of the sub-
stance (Van Hout & Brennan, 2012). Users who continued to use mephedrone kept it compartmentalized 
within house party and weekend club events, and they did not report any loss of control around use or 
cravings. Although this post-legislative study is limited to a small number of club drug users, it is sugges-
tive of a reduction in popularity of mephedrone due to a rise in emergence of good quality cocaine and 
MDMA in 2012. Research carried out in 2009/2010 also found that the desired social context for 
mephedrone use was portrayed as a shared experience in the company of a small number of close 
friends. The researchers found little evidence that would label mephedrone as a “club drug” (McElrath & 
O’Neill, 2010). Another Irish study with club drug users reported the use of mephedrone as both a club 
drug and a sexual stimulant (Van Hout & Brennan, 2011c). 4.5  Online Communities 
Irish users of NPS in pre-legislative studies were reported to be undeterred by the changes in legislative 
control and stated intentions to purchase and stock up on preferred products, use web based headshops, 
and to buy from dealers so they could continue use of NPS such as mephedrone (McElrath & O Neill, 
2011; McElrath & Van Hout, 2011; Van Hout & Brennan, 2011a; b). Irish research has shown that a great 
deal of trust is placed not only in peers, but in online discussion fora, amongst NPS users in Ireland. Ad-
vise on the use of mephedrone provided by both online drug user fora and headshop staff (pre-
legislation) was considered trustworthy and considered these sources to optimise safe usage and harm 
reduction for the users (McElrath & Van Hout, 2011). Van Hout & Brennan (2011) reported post-
legislative behaviours differed amongst some users in Ireland, some intending to return to street drug 
trade and thus continuing with illegal use of mephedrone; some users waited for varied cathinone deriva-
tives in headshops; and others considered the purchase of online sales of mephedrone. A more recent 
study by Irish researchers reported that users of the online marketplace “silk road” showed general wari-
ness toward untested NPS and seemed to limit their purchasing to more common illicit substances such 
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as cannabis, MDMA, cocaine, LSD, ketamine and heroin, which were deemed to be “safer” (Van Hout & 
Bingham, 2013). The media in Ireland has reported on the conviction of two Irish drug dealers active on 
the Dark Web, and dispatching drugs from Dublin to many global destinations (Bohan, 2014). 4.6  Problematic Users 
Research in Ireland highlights the potential some NPS products such as mephedrone or MDPV have for 
cravings, compulsive re-dosing and uncontrollable binge use (known as ‘fiending’), and how this is due to 
its short duration effect (2-3 hours) (Europol-EMCDDA, 2010). Problematic polydrug users have been 
reported as limiting their use (regularly injecting) to synthetic stimulants e.g. mephedrone and meth-
ylenedioxypyrovalerone, MDPV (Ryall & Butler, 2011; Van Hout & Bingham, 2012). 
 In February 2015, the Department of Public Health (DPH), Health Service Executive (HSE), recognised a 
sudden rise in the number of acute cases of HIV infection amongst PWID. In January and February 2015, 3 
cases were diagnosed p24 antigen-positive, in contrast with only 2 cases diagnosed throughout the whole 
of 2014 (Glynn et al., 2015). 
Drug treatment medical professionals had at that time recognised increased use of an NPS alphapyrroli-
dinovalerophenone (α-PVP), known on the street as “snow-blow”. This substance was described as being 
used by chaotic PWID, and they suspected it may have been related to the increase in HIV diagnoses. This 
study amongst chaotic PWID who were also homeless in Dublin, , presents the first known evidence of 
links between injecting of α-PVP and recent HIV infection, with daily injectors of the substance being at 
the greatest risk (Giese et al., 2015). These epidemiological outcomes are supported by α-PVP detected in 
urine samples of the cases. α-PVP is a second generation cathinone and is directly linked to MDPV, and 
exhibits similar abuse potential (Van Hout & Bingham, 2012; O’Byrne et al., 2013; Europol-EMCDDA, 
2015). 
The findings in the study are consistent with established effects of other synthetic cathinones and the 
risky injecting practices related to their use (Van Hout & Bingham, 2012; Cameron et al., 2014; Marusich 
et al., 2014; Watterson et al., 2014; Aarde et al., 2015). There are more than 500 homeless PWID in Dub-
lin, Ireland (Giese et al., 2015) and recent studies in Ireland have documented the use of synthetic cathi-
nones amongst homeless PWID (Van Hout & Bingham, 2012). 5 Prevention Activities 
A report by Kelleher et al. (2011) revealed the outcomes of an NPS review within the Irish perspective, 
which included a review of the markets supplying the substances. This review was authorized by the Na-
tional Advisory Committee on Drugs (NACD) in accordance with Action 14 of the National Drugs Strategy 
(interim) 2009–2016. Action 14 stipulates the monitoring of headshops and other sales outlets of NPS, 
under the Misuse of Drugs Act 1977 and the Misuse of Drugs (Amendment) Regulations 2007. The review 
was carried out between May and August 2010 by researchers at the Centre for Social and Educational 
Research (CSER) within the School of Social Sciences and Law at Dublin Institute of Technology (DIT), and 
at the School of Chemical and Pharmaceutical Sciences (DIT). This report recommended: - Efforts put in place to observe online monitoring models already in existence; - Collaborate more meticulously with UK and other EU countries’ initiatives that are aimed at con-
straining access to NPS. 
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- data collected at hospital level be centralised appropriately in agencies such as the Economic and 
Social Research Institute (ESRI) (which details hospital admissions each year), the Health Re-
search Board (HRB), or the National Advisory Committee on Drugs (NACD). This is so as to give a 
clearer, empirical representation of the harm being caused due to NPS thus replacing the system 
(which was present at that time) of reliance on anecdotal reporting - Standard reporting of NPS intoxication to the National Poisons Information Centre - Usage of online social media platforms such as Facebook, to give a much more dynamic stating 
of NPS risks. Additionally, placing advertisements there and actively engaging with chat room 
threads - Specifically targeted interventions towards polydrug substance users - In light of changes in consumption choices and patterns of NPS use due to legislative changes, 
the report recommended these changes be observed and assessed so as to identify any emerg-
ing new risks and to respond appropriately - The establishment of a laboratory specifically dedicated to rigorous testing of new and emerging 
NPS - Establishment of a reference standards company/body in Ireland that can respond more swiftly 
as new products appear on the NPS market  - Continually adopting a pragmatic public health approach to NPS. 5.1  Supply and Harm Reduction 
Ireland’s specific challenges for supply reduction include: NPS, precursor chemicals, synthetic opioid an-
algesics particularly tramadol, illicit production of coca bush, opium poppy, and cannabis plants, and illicit 
drug manufacture, supply, and trafficking (Pike, 2014). The National Drugs Strategy 2009-2016 endeav-
ours to monitor headshop activities (pre-legislation) and all other businesses concerned with NPS sales 
(e.g. online vendors), with the objective of guaranteeing no illegal actions are undertaken. This strategy 
also ensures that legislative steps are/were taken to in respect of NPS legality and where it is deemed 
appropriate, and to consistently monitor and review drugs related legislation, specifically in the area of 
NPS, and refer to EU and a wider international experience and best practice (Department of Health, 
2013a). Unfortunately demand reduction data such as custom and excise seizure data relating to NPS is 
unavailable in Ireland. 
Much harm reduction information in Ireland is based around needle exchange services aimed at reducing 
harm to injecting drug users and the spread of blood borne viruses (Van Hout & Hearne, 2015a). Howev-
er, some services have focused on NPS harm reduction. The Anna Liffey Drug Project, has distributed a 
brochure providing harm reduction information on novel psychoactive substances – “legal highs or oth-
erwise.” (Fig. 3). In 2010, the Health Service Executive (HSE) launched a national drug awareness cam-
paign “Legal or illegal highs – they’re anything but safe” (Fig.4). This campaign is predominantly aimed at 
individuals aged between 15 and 40 years. The campaign consisted of information on t-shirts, posters, 
and wallet cards; relating to the dangers of and harm reduction advice on NPS. The campaign also in-
cludes an information booklet for parents explaining all aspects of NPS use, legal issues, harm reduction 
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advice, and how to deal with someone having a negative reaction to a synthetic substance (Reitox Na-
tional Focal Point, 2011). 
Figure 3. The Ana Liffey Drug Project “legal highs or otherwise” leaflet 
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Figure 4. Health Service Executive national drug awareness campaign “Legal or illegal highs – they’re anything 
but safe” leaflet 
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5.2  Treatment 
This information is extremely limited in Ireland. However, one recent report showed the numbers of 
people seeking treatment for NPS as their primary problem substance in 2013 was minimal (Health Re-
search Board, 2015a). 5.3  NPS related Deaths 
Once laboratory standards were offered in 2009, NPS started to emerge in drug-related deaths in Ireland. 
The figures for NPS related deaths increased from 5 deaths in 2009 to 15 deaths in 2013. The majority of 
these deaths were related to polydrug use (Health Research Board, 2015b). The substances sold/used as 
MDMA-type substances - PMA (para-Methoxyamphetamine) and PMMA (para-Methoxy-N-
methylamphetamine) – were concerned with less than 5 deaths as recorded in 2012 (Health Research 
Board, 2015a). 6 Conclusions 
The report has presented extant available data on NPS in Ireland, and situated within the European con-
text for monitoring of trends, legislative controls and intervention activity. Given the recent legislative 
changes in Ireland, coupled with the decrease in NPS prevalence and availability of headshops, greater 
focus is still warranted to monitor online sourcing of NPS from Irish customers, continued harm reduction 
dissemination to all types of users and localised surveillance of new trends.  
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